Moreover, despite mutated KRAS is one of the most frequent (31%) alteration in NSCLC, it represents an unmet clinical need since no specific inhibitor has successfully progressed through clinical trials so far [9]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.